|Articles|January 19, 2021
Screening developability and pre-formulation by HT-DLS
Author(s)Wyatt Technology
Assessing a drug candidate early in discovery and development minimizes the risk of costly downstream failure. This white paper illustrates the application of automated DLS for aggregation and stability investigations.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
2
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
3
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
4
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
5
